Browse by entity family
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentionsPopular entities in these results
Choose an entity to see the articles in which it was identified.
Matching articles
29,499 articles · page 148 of 2459…Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359:97–103.Overacre-Delgoffe AE, Bumgar…
…Background Endometrial Cancer (EC) is the most common gynecologic malignancy in the United St…
…rcinoma (54%), head and neck squamous cell carcinoma (37%), and thyroid cancer (52%), but the distribution of mutations differs across these d…
… van Laarhoven HWM. Neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: a single-arm phase II…
…Background Glioblastoma (GBM) poses significant challenges for CAR-T therapy due to ant…
…d CD93 chimeric antigen receptor (CAR) T cells efficiently kill acute myeloid leukemia (AML) but risk endothelial cell (EC) toxicity due to CD93 expre…
…ells, both in vitro and in vivo. These results findings support SynKIR-110 as a promising candidate with improved safety and efficacy for …
…responses, and extended durability. By using the two therapies (177Lu-PSMA-617 and PSCA-CAR T cells) that are FDA approved or in clinical deve…
…o TIGIT-expressing cells, even in mixed populations.Conclusions Rilvegostomig’s potent, preferential TIGIT binding and cooperative PD-1 engag…
… rilvegostomig activity from conventional anti-PD-(L)1 therapy. Rilvegostomig was active in tumors with unique driver mutations, lower CD8+ T…